Related Experiment Video
Updated: Jul 17, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Expansion of Anticomplement Therapy Indications from Rare Genetic Disorders to Common Kidney Diseases
Takashi Miwa1, Sayaka Sato1, Madhu Golla1
1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; email: miwataka@pennmedicine.upenn.edu, sayakas@pennmedicine.upenn.edu, madhub@pennmedicine.upenn.edu, songwe@pennmedicine.upenn.edu.
Insights
Anticomplement therapies are shifting focus from rare diseases to common kidney diseases. This review highlights the growing importance of targeting complement overactivation for immune injury treatment.
Area of Science:
- Immunology
- Nephrology
Background:
- The complement system is crucial for innate immunity.
- Historically, research focused on complement deficiencies; now, overactivation is recognized as a cause of immune injury.
- Kidneys are highly susceptible to complement-mediated damage.
Purpose of the Study:
- To review the current status of anticomplement therapies.
- To emphasize the expansion of these therapies from rare to common kidney diseases.
Main Methods:
- Literature review of anticomplement therapies.
- Analysis of complement overactivation mechanisms in kidney diseases.
Main Results:
- Complement overactivation can stem from genetic mutations, autoantibodies, infections, or tissue stress.
- Anticomplement therapies are being investigated for various kidney diseases.
- Therapeutic strategies are evolving to address both rare and prevalent kidney conditions.
Conclusions:
- Anticomplement therapies represent a promising avenue for treating immune-mediated kidney diseases.
- The field is expanding to target more common renal pathologies beyond rare deficiencies.
Abstract:
Complement constitutes a major part of the innate immune system. The study of complement in human health has historically focused on infection risks associated with complement protein deficiencies; however, recent interest in the field has focused on overactivation of complement as a cause of immune injury and the development of anticomplement therapies to treat human diseases. The kidneys are particularly sensitive to complement injury, and anticomplement therapies for several kidney diseases have been investigated. Overactivation of complement can result from loss-of-function mutations in complement regulators; gain-of-function mutations in key complement proteins such as C3 and factor B; or autoantibody production, infection, or tissue stresses, such as ischemia and reperfusion, that perturb the balance of complement activation and regulation. Here, we provide a high-level review of the status of anticomplement therapies, with an emphasis on the transition from rare diseases to more common kidney diseases.
More Related Videos
Related Concept Videos
Kidney Transplant I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome I : Introduction
Chronic Kidney Disease II: Clinical Manifestations

